We are live on ! Find out more
IDYA icon

IDEAYA Biosciences

103 hedge funds and large institutions have $393M invested in IDEAYA Biosciences in 2022 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 43 increasing their positions, 31 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

39% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 31

0.59% more ownership

Funds ownership: 90.2%90.79% (+0.59%)

6% less funds holding

Funds holding: 110103 (-7)

37% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 19

52% less capital invested

Capital invested by funds: $820M → $393M (-$427M)

60% less funds holding in top 10

Funds holding in top 10: 52 (-3)

Holders
103
Holders Change
-7
Holders Change %
-6.36%
% of All Funds
1.62%
Holding in Top 10
2
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-60%
% of All Funds
0.03%
New
12
Increased
43
Reduced
31
Closed
19
Calls
$1.49M
Puts
Net Calls
+$1.49M
Net Calls Change
+$535K
Name Holding Trade Value Shares
Change
Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$2.15M +$1.29M +87,482 +84%
ACM
27
ACT Capital Management
Pennsylvania
$1.94M
Marshall Wace
28
Marshall Wace
United Kingdom
$1.87M +$2.41M +163,482 +4,920%
Bank of America
29
Bank of America
North Carolina
$1.85M +$811K +55,023 +50%
N
30
Nuveen
North Carolina
$1.74M +$483K +32,756 +28%
IBT
31
International Biotechnology Trust
United Kingdom
$1.62M
Millennium Management
32
Millennium Management
New York
$1.41M +$1.51M +102,769 +443%
Morgan Stanley
33
Morgan Stanley
New York
$1.35M +$1.2M +81,646 +208%
Bank of New York Mellon
34
Bank of New York Mellon
New York
$1.26M -$22.5K -1,528 -1%
Rafferty Asset Management
35
Rafferty Asset Management
New York
$1.22M +$32.9K +2,234 +2%
Ensign Peak Advisors
36
Ensign Peak Advisors
Utah
$1.06M +$34.9K +2,370 +3%
Charles Schwab
37
Charles Schwab
California
$958K +$31.1K +2,109 +3%
Two Sigma Advisers
38
Two Sigma Advisers
New York
$886K +$996K +67,600 +583%
UBS Group
39
UBS Group
Switzerland
$854K -$604K -40,996 -35%
CSS
40
Cubist Systematic Strategies
Connecticut
$847K +$1.1M +74,499 +6,182%
ECM
41
ExodusPoint Capital Management
New York
$742K +$977K +66,295 New
HF
42
HRT Financial
New York
$729K +$961K +65,226 New
Swiss National Bank
43
Swiss National Bank
Switzerland
$714K +$67.8K +4,600 +8%
JAMONY
44
Jacob Asset Management of New York
California
$704K +$163K +11,047 +21%
Ameriprise
45
Ameriprise
Minnesota
$688K -$31K -2,100 -3%
Manulife (Manufacturers Life Insurance)
46
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$671K +$629K +42,702 +247%
Wellington Management Group
47
Wellington Management Group
Massachusetts
$613K -$2.89K -196 -0.4%
GCP
48
GSA Capital Partners
United Kingdom
$607K +$589K +39,952 +280%
HS
49
HighVista Strategies
Massachusetts
$554K +$131K +8,908 +22%
Qube Research & Technologies (QRT)
50
Qube Research & Technologies (QRT)
United Kingdom
$546K +$720K +48,838 New

IDYA Hedge Fund Activity: Q1 2022 in Review

103 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in IDEAYA Biosciences (IDYA) for Q1 2022, worth a combined $393M — down 52% from $820M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of IDYA and 12 opened new positions — a net loss of 7 holders — while 31 trimmed existing stakes and 43 added.

The largest buyer was BVF Inc, opening a new position worth an estimated $23.6M. The largest seller was RTW Investments, exiting entirely with an estimated $59.6M sold.

  • 103 institutional investors held IDEAYA Biosciences (IDYA) as of Q1 2022, down from 110 in Q4 2021.
  • Funds reported $393M of IDEAYA Biosciences stock for Q1 2022, down 52% quarter-over-quarter.
  • 12 funds opened new IDEAYA Biosciences positions in Q1 2022 and 19 closed out, a net change of -7 holders.
  • The largest IDEAYA Biosciences buyer in Q1 2022 was BVF Inc, an estimated $23.6M added.
  • The largest IDEAYA Biosciences seller in Q1 2022 was RTW Investments, an estimated $59.6M sold.

Based on aggregated 13F filings for Q1 2022.